AbbVie: Alopecia Areata trials

The registry lists 12 Alopecia Areata studies with AbbVie as lead sponsor. 4 are open to participants now and 5 have results posted.

Phase 1 3Phase 2 3Phase 3 3Phase 4 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia AreataRecruitingNCT07772492Phase 3
• A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis SuppurativaRecruitingNCT07136467
• A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia AreataRecruitingNCT06012240Phase 3
• Expanded Access to UpadacitinibAvailableNCT04159597
• A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in MalesCompletedNCT02781311Phase 2Results posted
• A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)CompletedNCT01904721Phase 2Results posted
• Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic AlopeciaCompletedNCT01325337Phase 2Results posted
• Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With AlopeciaCompletedNCT01189279Phase 1Results posted
• Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in ChildrenCompletedNCT01023841Phase 4Results posted
• A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia AreataActive, not recruitingNCT07023302Phase 3
• Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic AlopeciaCompletedNCT02848300Phase 1
• Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)TerminatedNCT02676310Phase 1